Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02117050 · ClinicalTrials.gov registry record · Phase 4
RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
A Phase 4 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT02117050: Clinical Trial Phase 4 study, sponsored by EMD Serono.
NCT02117050 is a Phase 4 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02117050, a Phase 4 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment satisfaction in patients with relapsing forms of Multiple Sclerosis (MS) who are currently being treated with, but are considering discontinuing treatment with Tecfidera™.
Primary Outcome
The TSQM (Version II) is a validated tool that measures patient satisfaction with medical treatments using a 100-point scale. Global satisfaction sub-scale of TSQM was to be used to measure overall satisfaction with medication using a 100-point scale. Subject were to respond about their satisfaction or dissatisfaction with medication they are taking on a scale ranging from 0 to 100, where higher scores indicated greater satisfaction.
Interventions
- DRUG Rebif®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 4 |
Why NCT02117050 stopped before completion
NCT02117050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Rebif® is the first listed.
NCT02117050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02117050 about?
NCT02117050 is a clinical study titled "RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate". This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment satisfaction in patients with relapsing forms of Multiple Sclerosis (MS) who are currently being treated with, but are considering discontinuing treatment with Tecfidera™.
What is the current status of trial NCT02117050?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2014-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02117050?
The interventions under investigation include: Rebif® (DRUG).
Who is sponsoring clinical trial NCT02117050?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02117050's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia